Table 1.
Main characteristics at enrolment by intervention group.
| Characteristics | Regimen started | |||
|---|---|---|---|---|
| BAM/ETE | CAS/IMD | p-value* | Total | |
| N = 237 | N = 196 | N = 433 | ||
| Gender, n (%) | 0.701 | |||
| Female | 112 (47.3%) | 89 (45.4%) | 201 (46.4%) | |
| Age, years | 0.798 | |||
| Median (IQR) | 63 (53, 73) | 62 (53, 74) | 63 (53, 73) | |
| Days from sypmtoms onset to MAbs infusion | 0.624 | |||
| Median (IQR) | 5 (3, 6) | 5 (3, 6) | 5 (3, 6) | |
| Comorbidities/risk factors, n (%) | ||||
| Diabetes | 33 (14.0%) | 16 (8.2%) | 0.056 | 49 (11.4%) |
| Severe obesity (BMI>35) | 33 (13.9%) | 20 (10.2%) | 0.240 | 53 (12.2%) |
| Obesity (BMI>30) | 72 (30.4%) | 46 (23.5%) | 0.108 | 118 (27.3%) |
| Hypertension | 97 (41.5%) | 83 (42.6%) | 0.817 | 180 (42.0%) |
| Cardiovascular disease | 42 (17.9%) | 36 (18.5%) | 0.891 | 78 (18.2%) |
| Cerebrovascular disease | 10 (4.3%) | 10 (5.1%) | 0.669 | 20 (4.7%) |
| Chronic respiratory disease | 37 (15.7%) | 34 (17.3%) | 0.642 | 71 (16.4%) |
| Renal impairment | 4 (1.7%) | 1 (0.5%) | 0.250 | 5 (1.2%) |
| Neurologic disease | 7 (3.0%) | 9 (4.6%) | 0.378 | 16 (3.7%) |
| Autoimmune disease | 24 (10.2%) | 21 (10.7%) | 0.865 | 45 (10.4%) |
| Neoplasms | 19 (8.1%) | 15 (7.7%) | 0.879 | 34 (7.9%) |
| Hematologic disease | 13 (5.5%) | 13 (6.7%) | 0.623 | 26 (6.0%) |
| Immunodeficiency | 11 (4.9%) | 9 (4.7%) | 0.924 | 20 (4.8%) |
| Vital signs at baseline | ||||
| SpO2, median (IQR) | 97 (96, 98) | 97 (96, 98) | 0.289 | 97 (96, 98) |
| Fever (>37.5°C), n(%) | 12 (5.1%) | 14 (7.3%) | 0.342 | 26 (6.1%) |
| BMI, median (IQR) | 26.67 (23.71, 31.89) | 25.92 (23.10, 30.12) | 0.079 | 26.23 (23.46, 31.22) |
| Laboratory values, median (IQR) | ||||
| Ferritin, ng/ml | 161.5 (68.00, 274.0) | 179.0 (110.0, 313.0) | 173.0 (81.00, 296.0) | |
| C-reactive protein, mg/dl | 1.33 (0.52, 3.19) | 1.20 (0.49, 2.42) | 1.27 (0.50, 2.83) | |
| Lymphocytes,/uL | 1210 (850.0, 1600) | 1160 (880.0, 1530) | 1180 (870.0, 1560) | |
| Baseline SARS-COV-2 | ||||
| Serology, n (%) | <.001 | |||
| Positive | 104 (43.9%) | 112 (57.1%) | 216 (49.9%) | |
| Negative | 74 (31.2%) | 80 (40.8%) | 154 (35.6%) | |
| Unknown | 59 (24.9%) | 4 (2.0%) | 63 (14.5%) | |
| Vaccination, n (%) | 0.077 | |||
| Yes (partly or fully) | 140 (60.6%) | 101 (52.1%) | 241 (56.7%) | |
| Vaccine type, n (%) | 0.050 | |||
| BNT162b2 | 75 (68.8%) | 65 (68.4%) | 140 (68.6%) | |
| mRNA-1273 | 18 (16.5%) | 6 (6.3%) | 24 (11.8%) | |
| ChAdOx1 | 8 (7.3%) | 20 (21.1%) | 28 (13.7%) | |
| Ad26.COV2.S | 8 (7.3%) | 4 (4.2%) | 12 (5.9%) | |
| Other/unknown | 31 (22.1%) | 6 (5.9%) | 37 (15.4%) | |
| SARS-COV-2 variant, n (%) | 0.886 | |||
| B.1.1.7/Alpha | 34 (22.5%) | 37 (21.4%) | 71 (21.9%) | |
| P.1/Gamma | 14 (9.3%) | 11 (6.4%) | 25 (7.7%) | |
| B.1617.2/Delta | 87 (57.6%) | 105 (60.7%) | 192 (59.3%) | |
| Other VoC | 1 (0.7%) | 1 (0.6%) | 2 (0.6%) | |
| Not done | 15 (9.9%) | 19 (11.0%) | 34 (10.5%) | |
| Baseline CT, mean (SD) | 21.01 ± 6.46 | 20.14 ± 6.09 | 20.56 ± 6.28 | |
| MASS score, median (IQR) | 2 (0, 4) | 2 (0, 3) | 0.104 | 2 (0, 4) |
| Enrolled after June 2021, n (%) | 172 (72.6%) | 127 (64.8%) | 0.082 | 299 (69.1%) |
*Chi-square or Mann-Whitney test as appropriate.
BAM/ETE, bamlanivimab/etesevimab; CAS/IMD, casirivimab/imdevimab; IQR, interquartile range; BMI, body mass index; SpO2, peripheral oxygen saturation; MASS, Monoclonal Antibodies Screening Score.